United States-based biotech company, Rubius Therapeutics, has named Francis Cuss and Catherine Sohn as its new directors, it is reported today.

Cuss has spent 14 years in leadership roles at Bristol-Myers Squibb, most recently as its executive vice president and chief scientific officer, and he is currently a member of the Novo Nordisk board of directors.

Catherine Sohn, who is presently non-executive chairman of BioEclipse Therapeutics, has also joined the company's board. She has earlier served GlaxoSmithKline as senior vice president of worldwide business development and strategic alliances and before that was vice president of worldwide strategic product development for the cardiovascular, metabolic and pulmonary therapeutic areas at SmithKline Beecham pharmaceuticals.